#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14778	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2125	691.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1416	1416	C	847	C,G	790,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14778	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2125	691.5	0	HET	.	.	.	C1200T	.	1200	1200	C	1432	1432	C	831	C,T	581,192	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26954	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3540	759.2	0	.	n	.	0	T695C	SNP	695	695	T	1044	1044	C	741	C	693	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26954	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3540	759.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1686	1686	A	930	A	865	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26954	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3540	759.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2320	2320	C	829	C	764	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26954	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3540	759.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2946	2946	T	853	T,C	801,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26954	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3540	759.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2394	2394	A	861	A	812	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2054	folP	852	852	100.0	folP.l15.c4.ctg.1	1477	138.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1001	1003	AGC	205;206;205	A;G;C	193;194;193	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5764	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	169.1	1	SNP	p	S91F	0	.	.	271	273	TCC	609	611	TCC	189;188;191	T;C;C	171;171;173	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5764	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	169.1	1	SNP	p	D95G	0	.	.	283	285	GAC	621	623	GAC	197;199;196	G;A;C	183;186;184	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5764	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	169.1	1	SNP	p	D95N	0	.	.	283	285	GAC	621	623	GAC	197;199;196	G;A;C	183;186;184	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1682	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1397	120.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	484	486	ACC	207;208;208	A;C;C	188;194;192	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1682	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1397	120.0	0	.	p	.	0	R44H	NONSYN	130	132	CGC	499	501	CAC	209;211;211	C;A,G;C	193;190,1;195	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1682	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1397	120.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	682	684	CAC	233;233;233	C;A;C	214;211;215	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1682	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1397	120.0	1	SNP	p	G45D	0	.	.	133	135	GGC	502	504	GGC	211;214;213	G;G;C	196;199;199	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	872	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	900	96.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5614	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2849	196.1	1	SNP	p	D86N	0	.	.	256	258	GAC	522	524	GAC	221;220;223	G;A;C	199;195;200	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5614	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2849	196.1	1	SNP	p	S87I	0	.	.	259	261	AGT	525	527	AGT	228;228;223	A;G;T	206;207;200	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5614	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2849	196.1	1	SNP	p	S87R	0	.	.	259	261	AGT	525	527	AGT	228;228;223	A;G;T	206;207;200	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5614	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2849	196.1	1	SNP	p	S87W	0	.	.	259	261	AGT	525	527	AGT	228;228;223	A;G;T	206;207;200	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5614	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2849	196.1	1	SNP	p	S88P	0	.	.	262	264	TCC	528	530	TCC	221;222;221	T;C;C	197;199;198	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4528	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2665	169.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1573	1575	GGC	204;200;201	G;G;C	191;191;192	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1260	1262	GCA	219;214;217	G,T;C;A	204,1;200;204	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1263	1265	ATC	215;211;212	A;T;C	200;196;198	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1275	1277	GTG	220;222;219	G;T;G	211;209;210	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1275	1277	GTG	220;222;219	G;T;G	211;209;210	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1779	1781	ACC	221;220;220	A;C;C	198;201;205	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1833	1835	GCG	211;210;206	G;C;G,T	183;164;162,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1833	1835	GCG	211;210;206	G;C;G,T	183;164;162,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1956	1958	GGC	200;200;197	G;G;C	174;179;174	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1965	1967	GGC	186;182;177	G;G;C	162;157;150	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4056	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2431	166.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1983	1985	CCG	152;154;153	C,G;C,G;G,T	109,8;111,1;109,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6044	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3108	193.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1588	1590	CTG	218;218;216	C;T;G	199;199;199	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2508	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1717	145.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	467	467	C	168	C	150	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	342	porB1a	984	286	91.38	porB1a.l15.c30.ctg.1	1275	25.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1014	1016	AAT	19;20;19	A;A;T	19;20;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	342	porB1a	984	286	91.38	porB1a.l15.c30.ctg.1	1275	25.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1017	1019	AAT	19;20;20	A;A;T	19;20;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	342	porB1a	984	286	91.38	porB1a.l15.c30.ctg.1	1275	25.0	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1029	1031	GTT	22;22;23	G;T;T	22;22;23	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	342	porB1a	984	286	91.38	porB1a.l15.c30.ctg.1	1275	25.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1041	1043	GCA	24;24;24	G;C;A	24;24;24	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	342	porB1a	984	286	91.38	porB1a.l15.c30.ctg.1	1275	25.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1064	1066	GTA	26;26;25	G;T;A	26;26;25	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	342	porB1a	984	286	91.38	porB1a.l15.c30.ctg.1	1275	25.0	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1076	1076	G	33	G	32	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	426	428	GGA	240;243;245	G;G;A	227;228;227	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	0	.	p	.	0	T87A	NONSYN	259	261	ACT	543	545	GCT	219;220;219	G,A;C;T	198,1;198;190	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	687	689	CTT	220;222;221	C,G;T;T,G	205,1;206;206,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	711	713	GGA	212;211;208	G,A;G,A;A	196,1;195,1;192	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	0	.	p	.	0	D171G	NONSYN	511	513	GAT	795	797	GGT	193;198;202	G;G;TAA,TA	185;191;197,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	849	851	AGC	203;201;202	A;G;C	193;189;190	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	915	915	T	188	T	177	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	1	SNP	p	G120K	0	.	.	358	360	GGT	642	644	GGT	257;257;254	G,A;G,A;T	235,1;235,1;228	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	1	SNP	p	A121N	0	.	.	361	363	GCC	645	647	GCC	252;250;248	G;C,A;C	229;226,1;225	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2768	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1464	187.1	1	SNP	p	A121D	0	.	.	361	363	GCC	645	647	GCC	252;250;248	G;C,A;C	229;226,1;225	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10392	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	4820	215.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1954	1956	AAT	235;236;234	A;A;T	220;221;215	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1184	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	982	119.7	1	SNP	p	V57M	1	.	.	169	171	ATG	501	503	ATG	261;260;255	A;T;G	246;244;241	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
